Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse.

Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse.

Somatostatin receptor subtype 2 (SSTR2) is the most frequently expressed SSTR subtype in normal human tissues. SSTR2 expression is differentially regulated in various tumor types and therapeutic somatostatin analogs binding to SSTR2 are in clinical use. In prostate cancers highly contradictory resul...

Full description

Bibliographic Details
Main Authors: Jan K Hennigs, Julia Müller, Matti Adam, Joshua M Spin, Emilia Riedel, Markus Graefen, Carsten Bokemeyer, Guido Sauter, Hartwig Huland, Thorsten Schlomm, Sarah Minner
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4091868?pdf=render

Internet

http://europepmc.org/articles/PMC4091868?pdf=render

Similar Items